Gene Therapy – It's in our DNA

Here you can find an overview, information and news related to investor relations at AveXis, Inc. You will find links to view AveXis’ financial reports, including our latest performance report, annual reviews, and financial reports. These reports will help you to better understand AveXis from both a financial and…

Read More

REGENX BIOSCIENCES AND AVEXIS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY USING NAV® rAAV9 VECTORS WASHINGTON, DC and DALLAS, TX April 1, 2014 – REGENX Biosciences, LLC (REGENX) and…

Read More

In SMA, an insufficient amount of SMN (survival motor neuron) protein is produced, resulting in the death of motor neurons, which are specialized nerve cells controlling muscle movements. The reduced amount of SMN protein is caused by a loss of the SMN1 gene and the minimal production of SMN protein…

Read More

AveXis is dedicated to supporting families who are affected by Spinal Muscular Atrophy. We are proud sponsors of organizations like Families of Spinal Muscular Atrophy (FSMA), The Sophia’s Cure Foundation, and Avery’s Race who are trying to spread awareness and support to communities so that we…

Read More